EU Approves First Immunotherapy for Resistant Ovarian Cancer

Women across Europe now have access to a powerful new weapon against ovarian cancer that resists traditional treatments.

The European Commission just approved Keytruda, an immunotherapy drug, for use in combination with chemotherapy for patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. For the first time, European doctors can offer an immunotherapy option to eligible patients whose disease has stopped responding to standard platinum-based treatments.

The approval applies to adults whose tumors express a protein called PD-L1 and who have tried one or two previous treatments. Both the traditional infusion version and a newer under-the-skin injection form received the green light.

Keytruda works by removing the brakes on the immune system. Many cancer cells produce a protein that essentially tells immune cells to leave them alone. This drug blocks that signal, allowing the body's natural defenses to recognize and attack cancer cells more effectively.

The decision follows similar approval in the United States just two months earlier. Both authorizations relied on results from a major clinical trial called KEYNOTE-B96, which enrolled hundreds of patients across multiple countries.

Why This Inspires

The trial results showed real promise for patients who had run out of options. Among those with PD-L1-positive tumors, adding Keytruda to chemotherapy reduced the risk of disease progression or death by 28% compared to chemotherapy alone. The overall risk of death dropped by 24%.

For women facing platinum-resistant ovarian cancer, this approval represents more than just another treatment option. It's the first immunotherapy specifically authorized for this situation in Europe, opening a completely new avenue of care when previous therapies have failed.

Dr. Nicoletta Colombo, who directs the gynecologic oncology program at the European Institute of Oncology in Milan, called the approval "a welcome addition to the treatment landscape" for patients who face significant challenges when their cancer becomes resistant to standard therapy.

The timing matters. Ovarian cancer often becomes resistant to platinum-based chemotherapy, leaving patients and their doctors searching for effective alternatives. Now thousands of eligible patients across the EU have access to a treatment that harnesses their own immune systems in the fight against cancer.